Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease

PLoS One. 2012;7(1):e29868. doi: 10.1371/journal.pone.0029868. Epub 2012 Jan 18.

Abstract

There is an urgent need for biomarkers in plasma to identify Alzheimer's disease (AD). It has previously been shown that a signature of 18 plasma proteins can identify AD during pre-dementia and dementia stages (Ray et al, Nature Medicine, 2007). We quantified the same 18 proteins in plasma from 174 controls, 142 patients with AD, and 88 patients with other dementias. Only three of these proteins (EGF, PDGF-BB and MIP-1δ) differed significantly in plasma between controls and AD. The 18 proteins could classify patients with AD from controls with low diagnostic precision (area under the ROC curve was 63%). Moreover, they could not distinguish AD from other dementias. In conclusion, independent validation of results is important in explorative biomarker studies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / blood*
  • Alzheimer Disease / diagnosis*
  • Becaplermin
  • Biomarkers / blood*
  • Chemokines, CC / blood
  • Dementia / blood
  • Dementia / diagnosis
  • Epidermal Growth Factor / blood
  • Female
  • Humans
  • Macrophage Inflammatory Proteins / blood
  • Middle Aged
  • Predictive Value of Tests
  • Proto-Oncogene Proteins c-sis / blood
  • ROC Curve

Substances

  • Biomarkers
  • CCL15 protein, human
  • Chemokines, CC
  • Macrophage Inflammatory Proteins
  • Proto-Oncogene Proteins c-sis
  • Becaplermin
  • Epidermal Growth Factor